Doença de Kawasaki

Referências

Principais artigos

McCrindle BW, Rowley AH, Newburger JW, et al; American Heart Association. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017 Apr 25;135(17):e927-99.Texto completo  Resumo

Kawasaki T, Kosaki T, Okawa S, et al. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics. 1974 Sep;54(3):271-6. Resumo

Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991 Jun 6;324(23):1633-9. Resumo

Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr. 2005 May;146(5):662-7. Resumo

Artigos de referência

1. McCrindle BW, Rowley AH, Newburger JW, et al; American Heart Association. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017 Apr 25;135(17):e927-99.Texto completo  Resumo

2. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children [in Japanese]. Arerugi. 1967 Mar;16(3):178-222. Resumo

3. Mason WH, Takahashi M. Kawasaki syndrome. Clin Infect Dis. 1999 Feb;28(2):169-85. Resumo

4. Callinan LS, Holman RC, Vugia DJ, et al. Kawasaki disease hospitalization rate among children younger than 5 years of age in California, 2003-2010. Pediatr Infect Dis J. 2014 Jul;33(7):781-3. Resumo

5. Holman RC, Curns AT, Belay ED, et al. Kawasaki syndrome hospitalizations in the United States, 1997 and 2000. Pediatrics. 2003 Sep;112(3 Pt 1):495-501. Resumo

6. Holman RC, Belay ED, Clarke MJ, et al. Kawasaki syndrome among American Indian and Alaska native children. Pediatr Infect Dis J. 1999 May;18(5):451-5. Resumo

7. Yanagawa H, Nakamura Y, Ojima T, et al. Changes in epidemic patterns of Kawasaki disease in Japan. Pediatr Infect Dis J. 1999 Jan;18(1):64-6. Resumo

8. Yanagawa H, Yashiro M, Nakamura Y, et al. Nationwide surveillance of Kawasaki disease in Japan, 1984 to 1993. Pediatr Infect Dis J. 1995 Jan;14(1):69-71. Resumo

9. Dominguez SR, Anderson MS, Glode MP, et al. Blinded case-control study of the relationship between human coronavirus NL63 and Kawasaki syndrome. J Infect Dis. 2006 Dec 15;194(12):1697-701. Resumo

10. Abinun M, Cant AJ. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet. 1994 Jan 29;343(8892):300. Resumo

11. Meissner HC, Leung DY. Superantigens, conventional antigens and etiology of Kawasaki syndrome. Pediatr Infect Dis J. 2000 Feb;19(2):91-4. Resumo

12. Leung DY, Meissner HC, Fulton DR, et al. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet. 1993 Dec 4;342(8884):1385-8. Resumo

13. Rowley AH. Kawasaki disease: novel insights into etiology and genetic susceptibility. Annu Rev Med. 2011 Feb 18;62:69-77. Resumo

14. Hata A, Onouchi Y. Susceptibility genes for Kawasaki disease: toward implementation of personalized medicine. J Hum Genet. 2009 Feb;54(2):67-73. Resumo

15. Khor CC, Davila S, Breunis WB, et al. Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease. Nat Genet. 2011 Nov 13;43(12):1241-6. Resumo

16. Rowley AH, Shulman ST. New developments in the search for etiologic agent of Kawasaki disease. Curr Opin Pediatr. 2007 Feb;19(1):71-4. Resumo

17. Dajani AS, Taubert KA, Gerber MA, et al. Diagnosis and therapy of Kawasaki disease in children. Circulation. 1993 May;87(5):1776-80. Resumo

18. Takahashi K, Oharaseki T, Naoe S, et al. Neutrophilic involvement in the damage to coronary arteries in acute stage of Kawasaki disease. Pediatr Int. 2005 Jun;47(3):305-10. Resumo

19. Senzaki H. The pathophysiology of coronary artery aneurysms in Kawasaki disease: role of matrix metalloproteinases. Arch Dis Child. 2006 Oct;91(10):847-51.Texto completo  Resumo

20. Arnson Y, Shoenfeld Y, Amital H. Intravenous immunoglobulin therapy for autoimmune diseases. Autoimmunity. 2009 Sep;42(6):553-60. Resumo

21. Suzuki A, Miyagawa-Tomita S, Komatsu K, et al. Immunohistochemical study of apparently intact coronary artery in a child after Kawasaki disease. Pediatr Int. 2004 Oct;46(5):590-6. Resumo

22. Onouchi Y, Tamari M, Takahashi A, et al. A genomewide linkage analysis of Kawasaki disease: evidence for linkage to chromosome 12. J Hum Genet. 2007;52(2):179-90. Resumo

23. Satou GM, Giamelli J, Gewitz MH. Kawasaki disease: diagnosis, management, and long-term implications. Cardiol Rev. 2007 Jul-Aug;15(4):163-9. Resumo

24. Kawasaki T, Kosaki T, Okawa S, et al. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics. 1974 Sep;54(3):271-6. Resumo

25. Manlhiot C, Millar K, Golding F, et al. Improved classification of coronary artery abnormalities based only on coronary artery z-scores after Kawasaki disease. Pediatr Cardiol. 2009 Dec 19;31(2):242-9. Resumo

26. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004 Dec;114(6):1708-33.Texto completo  Resumo

27. Saguil A, Fargo M, Grogan S. Diagnosis and management of Kawasaki disease. Am Fam Physician. 2015 Mar 15;91(6):365-71.Texto completo  Resumo

28. Lee KY, Rhim JW, Kang JH. Kawasaki disease: laboratory findings and an immunopathogenesis on the premise of a "protein homeostasis system". Yonsei Med J. 2012 Mar;53(2):262-75.Texto completo  Resumo

29. Smith MT, Lester-Smith D, Zurynski Y, et al. Persistence of acute rheumatic fever in a tertiary children's hospital. J Paediatr Child Health. 2011 Apr;47(4):198-203. Resumo

30. Oates-Whitehead RM, Baumer JH, Haines L, et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2003 Oct 20;(4):CD004000.Texto completo  Resumo

31. Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991 Jun 6;324(23):1633-9. Resumo

32. Tremoulet AH, Best BM, Song S, et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr. 2008 Jul;153(1):117-21.Texto completo  Resumo

33. Sleeper LA, Minich LL, McCrindle BM, et al; Pediatric Heart Network Investigators. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr. 2011 May;158(5):831-35.e3.Texto completo  Resumo

34. Eleftheriou D, Levin M, Shingadia D, et al. Management of Kawasaki disease. Arch Dis Child. 2014 Jan;99(1):74-83.Texto completo  Resumo

35. Newburger JW, Sleeper LA, McCrindle BW; Pediatric Heart Network Investigators. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med. 2007 Feb 15;356(7):663-75.Texto completo  Resumo

36. Inoue Y, Okada Y, Shinohara M, et al. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J Pediatr. 2006 Sep;149(3):336-41. Resumo

37. Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet. 2012 Apr 28;379(9826):1613-20. Resumo

38. Furukawa T, Kishiro M, Akimoto K, et al. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child. 2008 Feb;93(2):142-6. Resumo

39. Okada K, Hara J, Maki I, et al. Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease. Eur J Pediatr. 2009 Feb;168(2):181-5. Resumo

40. Sundel RP, Baker AL, Fulton DR, et al. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. Pediatr. 2003 Jun;142(6):611-6. Resumo

41. Chen S, Dong Y, Yin Y, et al. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis. Heart. 2013 Jan;99(2):76-82. Resumo

42. Newburger JW. Kawasaki disease: medical therapies. Congenit Heart Dis. 2017 Sep;12(5):641-3. Resumo

43. Wardle AJ, Connolly GM, Seager MJ, et al. Corticosteroids for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2017 Jan 27;(1):CD011188.Texto completo  Resumo

44. Petty RE, Cassidy JT. Kawasaki disease. In: Cassidy JT, Petty RE, eds. Textbook of pediatric rheumatology. 4th ed. Philadelphia, PA: W.B. Saunders; 2001:580-94.

45. Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr. 2005 May;146(5):662-7. Resumo

46. Burns JC, Best BM, Mejias AJ, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2008 Dec;153(6):833-8.Texto completo  Resumo

47. Tremoulet AH, Jain S, Jaggi P, et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet. 2014 May 17;383(9930):1731-8. Resumo

48. Sonoda K, Mori M, Hokosaki T, et al. Infliximab plus plasma exchange rescue therapy in Kawasaki disease. J Pediatr. 2014 May;164(5):1128-32.e1. Resumo

49. de Ferranti SD, Steinberger J, Ameduri R, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association. Circulation. 2019 Mar 26;139(13):e603-34.Texto completo  Resumo

50. Chen S, Dong Y, Yin Y, et al. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis. Heart. 2013 Jan;99(2):76-82. Resumo

51. Zhu BH, Lv HT, Sun L, et al. A meta-analysis on the effect of corticosteroid therapy in Kawasaki disease. Eur J Pediatr. 2012 Mar;171(3):571-8.Texto completo  Resumo

52. Son MB, Newburger JW. Management of Kawasaki disease: corticosteroids revisited. Lancet. 2012 Apr 28;379(9826):1571-2. Resumo

53. Curtis N. Prednisolone added to intravenous immunoglobulin treatment improves outcome in children with severe Kawasaki disease. Arch Dis Child Educ Pract Ed. 2013 Apr;98(2):77-8. Resumo

54. Suda K, Tahara N, Honda A, et al. Statin reduces persistent coronary arterial inflammation evaluated by serial ¹⁸fluorodeoxyglucose positron emission tomography imaging long after Kawasaki disease. Int J Cardiol. 2014 Oct 22;179:61-2. Resumo

55. Beiser AS, Takahasha M, Baker AL, et al. A predictive instrument for coronary artery aneurysms in Kawasaki disease. US Multicenter Kawasaki Disease Study Group. Am J Cardiol. 1998 May 1;81(9):1116-20. Resumo

56. Mori M, Imagawa T, Yasui K, et al. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease. J Pediatr. J Pediatr. 2000 Aug;137(2):177-80. Resumo

57. Fukunishi M, Kikkawa M, Hamana K, et al. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset. J Pediatr. 2000 Aug;137(2):172-6. Resumo

58. Nakamura Y, Yashiro M, Uehara R, et al. Use of laboratory data to identify risk factors of giant coronary aneurysms due to Kawasaki disease. Pediatr Int. 2004 Feb;46(1):33-8. Resumo

59. Marquez J, Gedalia O, Candia L, et al. Kawasaki disease: clinical spectrum of 88 patients in a high-prevalence African-American population. J Natl Med Assoc. 2008 Jan;100(1):28-32. Resumo

60. Gersony WM. The adult after Kawasaki disease: the risks for late coronary events. J Am Coll Cardiol. 2009 Nov 17;54(21):1921-3.Texto completo  Resumo

61. Friedman KG, Gauvreau K, Hamaoka-Okamoto A, et al. Coronary artery aneurysm in Kawasaki disease: risk factors for progressive disease and adverse cardiac events in US population. J Am Heart Assoc. 2016 Sep 15;5(9):e003289.Texto completo  Resumo

O uso deste conteúdo está sujeito ao nosso aviso legal